Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Investor Day (May 2012)
109 slides from Orion Oyj Class A's investor day presentation, May 24, 2012
Slide 1: Orion CMD 2012
Orion CMD 2012 24 May 2012 in Helsinki
Slide 2: Agenda
Agenda Presentations part I Orion today Timo Lappalainen, President & CEO Market access of dexdor® Marjo Apajasalo, Director, Market Access & Support Proprietary Products update Liisa Hurme, SVP, Proprietary Products Q&A + coffee break Presentations part II Financial stability is basis for future Ja
Slide 3: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipa
Slide 4: Orion today
Orion today Timo Lappalainen President & CEO
Slide 5: Ownership base 2007-2011
Ownership base 2007-2011 Ownership structure by number of shares Number of shareholders 100 % 70000 80 % 60000 60 % 50000 40 % 40000 20 % 0% 30000 2007 2008 2009 2010 2011 20000 Households 10000 Foreign held and nominee registered Public sector 0 Private corporations Non-profit organisations 2007 20
Slide 6: Financial performance in 2007-2011
Financial performance in 2007-2011 Net Sales 2007-2011 Operating Profit 2007-2011 EUR million EUR million 1000 12,0 % 300 32,0 % 900 31,0 % 800 10,0 % 250 30,0 % 700 8,0 % 200 29,0 % 600 500 6,0 % 28,0 % 150 400 27,0 % 300 4,0 % 100 26,0 % 200 2,0 % 25,0 % 100 50 24,0 % 0 0,0 % 0 23,0 % 2007 2008 20
Slide 7: Net sales by business divisions 2007-2011
Net sales by business divisions 2007-2011 EUR million 1000 900 800 68 700 68 62 600 67 321 67 299 500 275 400 253 261 118 142 300 89 59 70 200 235 253 267 100 200 208 0 2007 2008 2009 2010 2011 Entacapone products Other Proprietary Products Specialty Products Animal Health Fermion Contract Manufactu
Slide 8: Development of key PP products
Development of key PP products EUR million EUR million 50 300 45 250 40 35 200 30 25 150 20 100 15 10 50 5 0 0 2007 2008 2009 2010 2011 2007 2008 2009 2010 2011 Simdax Precedex Easyhaler Stalevo, Comtess & Comtan 8 24 May 2012 Orion CMD 2012
Slide 9: Product protection situation of key products
Product protection situation of key products Key patents or data protection expire Molecule Product Indication Europe USA Japan Entacapone Stalevo®, Parkinson’s disease November 2012 October 2013 2) 2015 3) Comtess® and October 2013 1) Comtan® Levosimendan Simdax® Acute decompensated September Not m
Slide 10: Turning points of Parkinson's franchise
Turning points of Parkinsons’s franchise 2011 2012 2013 2014 2015 Comtess in-market Entacapone molecule patent expires Generic versions of Comtess sales EUR 35 11/2012 Europe million in 2011 Stalevo in-market Stalevo data protection ends 10/2013 Generic versions of sales EUR 250 Stalevo million in 2
Slide 11: Pharmaceutical market continues to grow
Pharmaceutical market continues to grow • The austerity measures of governments slow down the pharma market growth • In 2011, the global pharma market amounted to ca. EUR 600 billion • In 2012−2015, the global pharma market is estimated to grow 3−6% – Sales expected to exceed EUR 780 billion by the
Slide 12: Orion's strategy
Orion’s strategy Orion’s values Mutual trust Customer and respect focus Orion people Quality, Partners Innovation reliability and networks and safety Achievement Efficient and competitive operations Management of complexity in cost efficient way 12 24 May 2012 Orion CMD 2012
Slide 13: Balancing mid-term − building long-term
Balancing mid-term − building long-term Upside potential from long-term portfolio management Larger portfolio in the Nordics Parkinson’s franchise post patent Continued growth in Eastern Europe and Russia Precedex royalty stream post patent Contract Manufacturing Easyhaler combinations Pricing press
Slide 14: Slide 14
Slide 15: Market access of dexdor
Market access of dexdor® Marjo Apajasalo
Slide 16: Obtaining marketing authorization is no longer the only hurdle
Obtaining marketing authorization is no longer the only hurdle on the way to commercial success On-going Orion commercialisation projects 1 2 3 4 5 EU level National level +++ National / Regional / Local (EMEA) Regional level + (e.g., sickness funds, regional health authorities and hospitals) Added
Slide 17: Added value of dexdor
Added value of dexdor® GRION Building well-being
Slide 18: The Unmet Need in ICU sedation
The Unmet Need in ICU sedation There is an unmet need for a sedative that: Improves cooperativeness and communication with patients Reduces the complications related to current sedatives and mechanical ventilation Enables shortening of ICU stay 18 24 May 2012 Orion CMD 2012
Slide 19: ICU patients are critically ill
ICU patients are critically ill Unmet Need • Patients have an organ failure or a threat of developing an organ failure, that can lead to death if left untreated • Typical patients – Sepsis (infection with multiorgan failure) – Respiratory failure, e.g. due to pneumonia/neuromuscular disease – Severe
Slide 20: The goals in sedation have changed towards lighter sedation
The goals in sedation have changed Unmet Need considerably towards lighter sedation 1981: Presently: • Patients should To have patients who ideally be “detached are: from the ICU • Calm and rousable environment” • Able to communicate their needs • Co-operative and accepting of care There is convinci
Slide 21: The burden of ICU care and prolonged ICU stay is high
The burden of ICU care and prolonged Unmet Need ICU stay is high • There are ≈3.7 million ICU admissions/year in EU Big 5 and Nordic • ICUs can consume up to 20% of hospital budgets – Sedation and analgesia represents only a small % of the total ICU costs • On average, a patient at ICU costs ca EUR
Slide 22: Current sedatives contribute to certain complications in ICU patients
Current sedatives contribute to certain complications in ICU patients Communication and Delirium Prolonged mechanical co-operation ventilation challenging Increased mortality, Ventilator associated Suboptimal treatment prolongation of ICU pneumonia, ICU of pain/assessment of and hospital stay,
Slide 23: Therapeutic benefit of dexdor – basic facts
Therapeutic benefit of dexdor® – basic facts dexdor® is a highly selective alfa 2c adrenoreceptor agonist indicated for sedation of adult ICU patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0
Slide 24: dexdor addresses many of the unmet needs
Therapeutic dexdor® addresses many of the unmet needs Benefit Allows patients to be Reduces delirium Shortens invasive calm, arousable and mechanical ventilation communicative Refs: Whipple et al, 1995; Payen et al, 2007; Jacobi et al, 2002 ; Novaes et al, 1999; Ely et al, 2004; Pandharipande et al,
Slide 25: dexdor treated patients more arousable, co-operative and communicative
Therapeutic dexdor® treated patients were significantly more arousable, co- Benefit operative and better able to communicate than with propofol or midazolam 70 70 P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 60 60 59 59 50 50 49 48 49 48 47 47 40 40 Points Points 38 38 30 35 30 35 20 20 10 10 0 0
Slide 26: Significantly less delirium than patients on standard care
Therapeutic ICU patients sedated with dexdor® experienced Benefit significantly less delirium than patients on standard care In PRODEX, delirium- related neurocognitive adverse events* were observed in 18.3% of the dexdor® and 28.7% of the propofol patients (p=0.008) 229 206 175 134 92 60 44 N= 118
Slide 27: dexdor shortened the time to extubation by 1-2 days
Therapeutic dexdor® shortened the time to extubation Benefit by 1-2 days vs. standard care 4 7 Gehan-Wilcoxon Gehan-Wilcoxon p=0.041 p=0.012 3,5 6 -1.0 Median time to extubation from Median time to extubation from 3 days 5 -1.9 randomization (days) randomization (days) 2,5 days 4 2 3 1,5 2 1 2.9 3.9
Slide 28: Economic benefit of dexdor
Economic benefit of dexdor® dexdor® provides cost savings to the hospital and society 28 24 May 2012 Orion CMD 2012
Slide 29: dexdor provides ICU savings of over €1800 per patient
dexdor® provides ICU savings of over €1800 per patient vs. Economic Benefit standard care. Even in countries with low unit costs, dexdor® remains clearly cost-saving 3600 Mean savings in ICU costs, €/patient 3300 3000 2700 2400 2100 1837 1800 1500 The result with 1200 average European 900 unit costs
Slide 30: Conclusions from the pharmacoeconomic analysis
Conclusions from the pharmacoeconomic Economic Benefit analysis • dexdor® improves the quality of sedation and facilitates patient management compared to standard care • dexdor® is likely to reduce the total ICU costs significantly compared to standard care • dexdor® has the potential to improve ICU
Slide 31: Market access status of dexdor
Market access status of dexdor®
Slide 32: National market access process are lengthy
National market access process are lengthy Average time (days) elapsed between date of market authorisation and "accessibility" date Belgium Portugal Spain Italy France 0 50 100 150 200 250 300 350 400 450 For new medicines with first EU marketing authorisation in the period 2007-’09 Source: EFPIA,
Slide 33: dexdor market access timelines
dexdor® market access timelines 2011 2012 FI DE DK PL UA EE SI SK SE NO IE LT HU AT NL Pending UK* CZ RU CH ES FR PT BG LV GR IT BE RO *SMC and AWMSG assessment processes on-going 33 24 May 2012 Orion CMD 2012
Slide 34: Slide 34
Slide 35: Proprietary Products Update
Proprietary Products Update Liisa Hurme Senior Vice President
Slide 36: Entacapone franchise update
Entacapone franchise update
Slide 37: Entacapone brands are the leading global anti-PD drugs
Entacapone brands are the leading global anti-PD drugs Top-selling anti-PD franchise in the world EUR/MNF (millions) 600 568 500 504 400 300 304 277 200 197 100 115 107 90 0 Stalevo/ Sifrol Azilect Requip Madopar Sinemet Neupro Duodopa Comtess/ Comtan 37 24 May 2012 Orion CMD 2012
Slide 38: Prescription shares in USA after generic launches
Prescription shares in USA after generic launches Stalevo (levodopa/carbidopa/entacapone) - MS% of TRx 100 % 90 % 80 % 70 % 60 % 50 % Novartis, 52 % 40 % 30 % Sun, 33 % 20 % 10 % Wockhardt, 15 % 0% TRx TRx TRx TRx TRx TRx TRx 2012/03/30 2012/04/06 2012/04/13 2012/04/20 2012/04/27 2012/05/04 2012/05/
Slide 39: Growth potential in Europe and Rest of the World
Growth potential in Europe and Rest of the World • Stalevo volume growth in Europe 3,8% (2011 vs. 2010, IMS Health, EUR/MNF) • Stalevo protection in Europe – Data protection until October 2013 (first launches expected H2/2014) • RoW region is growing both in volume and value 13,1 % and 5,9% (2011 vs
Slide 40: Paving the way for new Easyhaler products
Paving the way for new Easyaler products
Slide 41: Preparing for Easyhaler combination product launches
Preparing for Easyhaler combination product launches • Orion is repatriating countries as Number of countries EUR million 30 35 license agreements expire – YTD growth in Orion territory +12% 25 30 • Customers and market access 25 20 dynamics in Orion hands 20 – Repeating Simdax aquisition model 15 b
Slide 42: Easyhaler market share in some key markets
Easyhaler market share in some key markets 25% 20% 15% 10% 5% 0% Finland Germany Turkey UK Sweden 2010 2011 Source: IMS Health 2011, Market share Easyhaler corticosteroid products of the total inhaled corticosteroid market 42 24 May 2012 Orion CMD 2012
Slide 43: Orion is a unique player in European Critical Care market
Orion is a unique player in European Critical Care market
Slide 44: Orion is a unique provider of innovative treatments in Critical Care
Orion is a unique provider of innovative treatments in Critical Care Major Critical Care Products Launched in Europe since 2000 OTHERS (Including • Total number of 17 SIMDAX (Orion) Dexdor) new products were launched in critical care sector between METALYSE 2000-2011 including (Boehringer) XIGRIS (L
Slide 45: European sales force in evolution
European sales force in evolution
Slide 46: Expansion of Orion brands and sales force in Europe
Expansion of Orion brands and sales force in Europe provides flexibility of resourcing 2008 2012 46 24 May 2012 Orion CMD 2012
Slide 47: Proprietary Products way forward
Proprietary Products way forward • Evolution from neurology focused Northern European company into multi product European company • Entacapone franchise will be significant part of the Proprietary Division in mid and long term perspective • Key areas in addition to neurology will be respiratory dise
Slide 48: Slide 48
Slide 49: Financial stability is basis for future success
Financial stability is basis for future success Jari Karlson CFO
Slide 50: Orion has solid financial position
Orion has solid financial position • Orion has solid financial position Equity ratio which provides good basis for 75 future development of the 70 65 company 60 • Maintaining financial strength is 55 50 an important goal for Orion 2007 2008 2009 2010 2011 – Capacity to take required R&D risks – Capa
Slide 51: Efficiency has been part of financial objectives and strategy
Efficiency has been part of financial objectives and strategy for years Net sales and profitability in next few years depend on rate of: • Decline in sales of Parkinson’s drugs • Growth in sales of other products Orion’s financial objectives: • Ensuring financial stability • Creating foundation for
Slide 52: Use of cash (during 2011)
Use of cash (during 2011) Current Business Investment for future Profit distribution (575 MEUR) (110 MEUR) (260 MEUR) NET SALES COGS GROSS PROFIT Largest growth investment (85 MEUR) SG&A for old portfolio New S&M activities R&D for old portfolio (launches, ..) EBITDA Most of R&D Maintenance
Slide 53: Orion's productivity has improved
Orion’s productivity has improved Sales per person Change (€ 1,000) 2007 2012 % 290 Net sales 680 918 +25% (EUR million) 270 Personnel 3,176 3425 +8% 250 Sales/person 184 268 +35% 230 (EUR thousand) 210 • Economics of scale • Networking 190 • Continous improvement 170 • Cost control 150 2007 2008 20
Slide 54: Re-allocation of resources support growth
Re-allocation of resources support growth Resources by function (EUR million) 350 Automation, centralization, 41 300 39 standadization 50 250 52 88 R&D networking 39 86 More with same cost 200 95 Timing of phase III studies 85 90 150 Growth drivers: Geographical expansion and other 100 205 g
Slide 55: Product launches
Product launches • Investments for future • Increase complexity Impact on costs and net working capital Orion’s product launches of Specialty product Proprietary Product human pharmaceuticals launches in 2011 launches in 2011 Number of product/country combinations By geographical area By geographi
Slide 56: Development of Net working capital
Development of Net working capital % of net sales EUR million 40 % 250 200 30 % 150 20 % 100 10 % 50 0 0% -50 -10 % -100 -20 % -150 12/09 12/07 12/08 12/10 12/11 12/07 12/08 12/09 12/10 12/11 6/07 6/08 6/09 6/10 6/11 6/07 6/08 6/09 6/10 6/11 Receivables Inventories Short-term non-interest bearing li
Slide 57: Development of Receivables
Development of Receivables • Growth mainly from unexpired 200,0 EUR million 180,0 trade receivables which have 160,0 increased clearly faster than 140,0 120,0 sales 100,0 – About 25 million of the growth 80,0 is due to small change in one 60,0 40,0 distribution agreement 20,0 – Growth in sales in re
Slide 58: Capital expenditure
Capital expenditure • Tangible capex has been 70 EUR million relatively consistent over the 60 last years 50 • Volatility in the overall capex 40 24 35 19 20 has been due to investments 8 15 30 to intangible assets which are mainly generated by in- 20 25 23 22 19 22 21 licensing of products 10 5 8 4
Slide 59: Dividend distribution
Dividend distribution Dividend distribution policy Dividend distribution history EUR • Orion’s dividend distribution takes 1,60 160 % into account distributable funds and 1,40 140 % capital expenditure and other 1,20 120 % financial requirements in medium 1,00 100 % and long term to achieve the 0,80
Slide 60: Equity structure and Profit distribution
Equity structure and Profit distribution Orion Orion 31 Dec 2011 (EUR million) Corporation Group Share capital 92.2 92.2 Of these 200 million was Reserves 18.3 18.1 distributed in April 2012 Retained earnings left EUR Orion Corporation 229.4 229.4 0,34/share Subsidiaries 37.0 IFRS and Consolidatio
Slide 61: Summary
Summary Increasing complexity of the Capital allocation decisions No easy short cuts on-going business makes it are increasingly important challenging to improve the cash conversion • More countries, larger product • Allocation between current • Tights management of numerous portfolios, large number
Slide 62: GRION
GRION Building well-being
Slide 63: Orion R&D pipeline review
Orion R&D pipeline review Reijo Salonen, SVP, Research & Development
Slide 64: The Best R&D in the World by 2017 – a goal set in 2008
The Best R&D in the World by 2017 – a goal set in 2008 Best Structure Best Leadership Best Image Best Strategy Best R&D in the world and continous improvement Superior return on R&D Investment – higher value R&D assets and more drugs generated, faster and at lower cost per unit of funding, than any
Slide 65: Internal R&D capability: optimized to bring products to Proof of concept
Internal R&D capability: optimized to bring products to Proof of concept (POC) First- Marketing Start R&D in- Proof Authorisation Project Candidate Human Concept Application New Pre- MarketAc PoI Research Exploratory Development Confirmatory Development Reg. Idea Clinical cess DP R&D partnerships an
Slide 66: Research projects 2006 (6)
Research projects 2006 (6) Active-To-Hit Hit-To-Lead Lead Optimization CNS A CNS B CNS C Oncology A Urology Cardiovascular Precandidate Candidate CTA 66 24 May 2012 Orion CMD 2012 30
Slide 67: Research projects 2012 (18)
Research projects 2012 (18) HIT Finding Active-To-Hit Hit-To-Lead Lead Optimization ENDO collaboration in oncology 4x Oncology A Oncology B Oncology C Oncology D CNS A CNS B CNS B CNS C CNS D CNS E CNS F CNS G CNS H Super generic Oncology spin out for new indication Precandidate Candidate CTA 67 24
Slide 68: Optimized R&D portfolio balance
Optimized R&D portfolio balance High Super Generics Generics Probability of success Technical feasibility Second generation compounds New validated targets which belong to drugable families (such as own platform) New unvalidated targets Low Low Commercial potential High (why dot it) 68 24 May 2012 O
Slide 69: Optimized R&D portfolio balance
Optimized R&D portfolio balance High Potential blockbuster Super Generics in late FIII & MAA Generics CNS Probability of success Technical feasibility CNS CC Second generation CNS Oncology Oncologycompounds Oncology CNS Oncology CNS Oncology Oncology CNS New validated targets CNS which belong to dru
Slide 70: Easyhaler combinations
Easyhaler combinations
Slide 71: Stepwise approach as outlined in EMA guidelines on orally inhaled products
Stepwise approach as outlined in EMA guidelines on orally inhaled products* Yes In vitro evaluation No Yes Yes Lung deposition Systemic exposure APPROVAL No Yes Pharmacodynamics No No Yes Phase III No Rejection * CPMP/EWP/4151/00 Rev. 1 71 24 May 2012 Orion CMD 2012
Slide 72: Key features of the studies
Key features of the studies • Acceptance criteria in step 2: classical bioequivalence criteria 0.8 – 1.25 for a test/reference product ratio of the primary parameters (Cmax, AUC) • To meet the criteria studies need to demonstrate not only small mean differences but also a low variability in results
Slide 73: Examples of product comparisons - start point
Examples of product comparisons - start point 2 Test/Reference ratio and 90% CI 1,8 1,6 1,4 1,2 1 0,8 0,6 0,4 PK parameter 1 PK parameter 2 73 24 May 2012 Orion CMD 2012
Slide 74: Examples of product comparisons - end point
Examples of product comparisons - end point 2 Test/Reference ratio and 90% CI 1,8 1,6 1,4 1,2 1 0,8 0,6 0,4 PK parameter 1 PK parameter 2 74 24 May 2012 Orion CMD 2012
Slide 75: Easyhaler Accurate and Consistent Dosing
Easyhaler® Accurate and Consistent Dosing Palander et al. Clin Drug Invest 2000; 20:25-33 75 24 May 2012 Orion CMD 2012
Slide 76: ODM-101
GRION Building well-being
Slide 77: Background for ODM-101 project
Background for ODM-101 project Product APIs Target indications Formulation Stalevo levodopa, Parkinson´s Currently seven carbidopa, disease and end- different strenghts entacapone of-dose motor fluctuations ODM-101 levodopa, Parkinson´s The ratios, carbidopa, disease and end- strengths and entacapon
Slide 78: Status of development of ODM-101
Status of development of ODM-101 Phase I Phase II Pharmacokinetics studies Efficacy and safety study completed ongoing with Parkinson´s disease patients 78 24 May 2012 Orion CMD 2012
Slide 79: Alpha-2C adrenoceptor antagonist
Alpha-2C adrenoceptor antagonist
Slide 80: Background for Alpha-2C project
Background for Alpha-2C project • Alpha-2 adrenoceptors (AR) are promising drug targets having key modulatory role in adrenergic neurotransmission • Orion has built a successful proprietary Alpha-2 adrenoceptor Platform (Domosedan® , Domitor® , Precedex® , dexdor , Antisedan®) which has generated ex
Slide 81: Status of development of ORM-12741 in Alzheimer's disease
Status of development of ORM-12741 in cognition enhancement in Alzheimer’s disease Phase I Phase II Completed and reported Efficacy and safety study ongoing with Alzheimer’s disease patients 81 24 May 2012 Orion CMD 2012
Slide 82: ODM-201 a new generation antiandrogen for CRPC
ODM-201 a new generation antiandrogen, for the treatment of CRPC
Slide 83: Orion and Endo Pharmaceuticals R&D collaboration
Orion Corporation and Endo Pharmaceuticals R&D collaboration strengthens further oncology presence • Collaboration agreement for the discovery, development and commercialization of assets in Oncology between North Americas and Europe • R&D collaboration partnership allows to bring forward a total of
Slide 84: High unmet need for Castration Resistant Prostate Cancer
High unmet need for Castration Resistant Prostate Cancer Death Androgen Chemotherapy deprivation Local Tumor therapy MDV3100 volume Zytiga Alpharadin & activity Asymptomatic Symptomatic Non-metastatic Metastatic Hormone-sensitive Castration-resistant A B C 1 2 3 4 Time CRPC Abbreviations: CRPC castr
Slide 85: ODM-201, a new generation antiandrogen, for the treatment of CRPC
ODM-201, a new generation antiandrogen, for the treatment of CRPC • Potentially best-in-class antiandrogen • Does not enter brain in preclinical models – No testosterone increase in animal models • Well tolerated (1) Foster & al .: Drug Safety Is a Barrier to the Discovery and Development of New And
Slide 86: Study design
Study design ARADES 3104001 Phase I dose escalation ARADES-EXT 3104002 component ongoing at 700 mg dose level After 12 weeks patients with stable • 3+3 rule-based design disease can continue study treatment in Arades extension study Day 28 Wk 12 2x100 mg 2x200 mg 2x300 mg 2x500 mg 2x700 mg 2x900 mg
Slide 87: Status of development of ODM-201
Status of development of ODM-201 Phase I/II study ongoing Phase I/II study results will be presented in a major scientific meeting in 2012 or 2013 87 24 May 2012 Orion CMD 2012
Slide 88: Building well-being
Building well-being
Slide 89: Specialty Products Success Story in Finland
Specialty Products Success Story in Finland Markku Huhta-Koivisto Senior Vice President
Slide 90: Orion clear market leader in Finland MAT 4/2012
Orion clear market leader in Finland MAT 4/2012 pharmacy and hospital market Finnish human pharmaceuticals and Finland’s biggest pharmaceutical self care market MAT 4/2012 companies MAT 4/2012 EUR million • Wholesale EUR 2105 million (+3%) 250 237 Orion in Finnish human 200 pharmaceuticals and self
Slide 91: Finnish market features and changes
Finnish market features and changes Some special features in the structure Orion’s market share in Finland in • efficient exclusive single channel pharmacies and hospitals MAT4/2012 wholesales distribution system 12 % 11 11,1 11,3 10,5 10,3 10,3 10,7 • pharmacies are private businesses, no 9,4 9,6 9
Slide 92: Orion Pharma in Finland MAT 4/2012
Orion Pharma in Finland MAT 4/2012 Finnish pharmacy and hospital market in Orion Pharma’s human products sales in MAT 4/2012 Finland MAT4/2012 EUR million PP • Wholesale EUR 2105 million (+2,7%) 21 Orion in Finnish pharmacy and hospital Non Market in MAT 4/2012 medicines 29 • Sales growth 6% – Rx sa
Slide 93: Orion's Best-selling brands in Finland
Orion’s Best-selling brands in Finland Orion’s best-selling brands, EUR million MAT4/2012 Change % 1. Burana, OTC & Rx (Inflammatory pain) 21.4 +8% 2. Primaspan, OTC (Antiplatelet) 7.2 +7% 3. Kefexin, Rx (Antibiotic) 5.6 +3% 4. Aqualan, OTC & Rx (Basic ointment series) 5.2 +1% 5. Stalevo, Rx, Propri
Slide 94: Specialty products sales in Finland
Orion clear market leader in Finland MAT 4/2012 2003 Specialty Products Business Specialty products sales in Finland started in Orion MAT4/2012 EUR million 2005 Very high sales at the end of 220 206 200 the year due to the changes 1.1.2006 200 185 189 2005 SpP made 4 launhces 180 177 2007 SpP ma
Slide 95: Key Success Factors
Key Success Factors • Continuous development and renewal of product portfolio. • Very high volume share • Service: availability, volume, variability and demand integration within supply chain, Pharmaservice • Long term commitment to the market and distribution channel • Lean and mean organisation up
Slide 96: The best pharmaceutical companies within substitution
The best pharmaceutical companies within substitution What pharmaceutical company working within substitution products, you consider overall the best? 70 60 50 40 30 20 10 0 Orion 2nd best 3rd best Pharmacy Owner Pharmacist Assistant Pharmacist Source: Orion Pharma Pharmacy Study by Success Clinic 2
Slide 97: Summary of the development of key ratios
Summary of the development of key ratios 2010 2009 Aided awareness (knows at least to some extent) Orion 97 % (1.) 99 % (1.) Median 80 % (7.) 93 % (5.) The worst 31 % (16.) 22 % (16.) Overall appreciation (excellent or average) Orion 90 % (1.) 95 % (1.) Median 85 % (3.) 87 % (3.) The worst 52 % (16.
Slide 98: Slide 98
Slide 99: Orion Supply Chain Key success factors
Orion Supply Chain Key success factors Virve Laitinen SVP, Supply Chain
Slide 100: Orion Pharma Supply Chain network
Orion Pharma Supply Chain network Suppliers Production Sites Partners & own Customers sales • 2 own API plants by • 3 own final product • Orion subsidiaries • Human products Fermion manufacturing sites • European wide • Veterinary products wholesalers and • Suppliers for • External distributors netw
Slide 101: Key priorities for Supply Chain
Key priorities for Supply Chain Service level Quality Complexity Operations management efficiency • High service level: • Compliance quality: • Integrated supply • Continuous operations products on time EU, USA and Japan chain planning make or buy delivery GMP approved evaluations • Different operat
Slide 102: Orion – Supply Chain operating models
Orion – Supply Chain operating models Fully integrated Orion Own In-licensed Contract Supply Chain production product supplies Manufacturing supplies partners • Fermion API + Orion • Lean bulk • Strategic network building Final product manufacturing and • proprietary and other agile packaging strate
Slide 103: Orion – Special production capabilities
Orion – Special production capabilities Inhalation production • Easyhaler specific manufacturing technology in-house • Investment program on-going to increase capacity Hormone gel production • Own expertise build through Divigel product portfolio • Contract manufacturing partner for Axiron Eli Lilly
Slide 104: Orion - Production capabilities
Orion - Production capabilities Tablet production • Tablet manufacturing capacity • Espoo:large scale manufacturing • Turku:small scale manufacturing Small volume parenteral production • Ampouls and injections Turku plant Kuopio plant • Sytostatics tablets • Liquids and solutions • Hormone tablets •
Slide 105: Orion as a Contract Manufacturing partner
Orion as a Contract Manufacturing partner CM Net Sales Contract manufacturing offering EUR Million 35 30 25 Pharmaceutical manufacturing Api contract and packaging 20 Including research and manufacturing Pharmaceutical 15 & Regulatory Support 10 Business development opportunities 5 Co-op in Marketin
Slide 106: How do we improve our operations?
How do we improve our operations ? Total Quality Efficiency Costs Agility Management • Quality • Productivity • In-direct • Sales and techniques in use: improvement ; purchasing operation green belt and TPM, 5S, SMED planning with black belt tools tools • Streamlined integrated processes and plannin
Slide 107: Key success factors for Orion Supply Chain
Key success factors for Orion Supply Chain Continuous improvement : quality and efficiency High service level End to end supply chain optimisation Networking and partnerships 107 24 May 2012 Orion CMD 2012
Slide 108: Slide 108
Slide 109: Slide 109